The American Hospital Association's initial comment on the Health Resources and Services Administration’s (HRSA) request for information regarding a 340B Rebate Model Pilot Program.

The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program.

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

HHS is scrapping its proposed 340B rebate pilot after hospitals sued to stop it. Providers say the plan would have created cash flow problems and administrative burdens that threatened safety-net care ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

Sen. Ed Charbonneau, R-Valparaiso, rolls up paperwork while listening to colleagues speak about his bill on Feb. 20. (Leslie Bonilla Muñiz/Indiana Capital Chronicle) A somewhat obscure federal program ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...

An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...